Commentary on the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder.
作者信息
Zarate Carlos A
机构信息
Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, 2511National Institutes of Health, Bethesda, MD, USA.
出版信息
Can J Psychiatry. 2021 Jun;66(6):537-539. doi: 10.1177/07067437211004023. Epub 2021 Mar 19.
Abstract
摘要
相似文献
1
Commentary on the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder.加拿大情绪与焦虑治疗网络（CANMAT）工作组关于在成年重度抑郁症患者中使用消旋氯胺酮的建议评论。
Can J Psychiatry. 2021 Jun;66(6):537-539. doi: 10.1177/07067437211004023. Epub 2021 Mar 19.
2
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.加拿大心境与焦虑治疗网络（CANMAT）成人重性抑郁障碍使用消旋卡前列甲酯治疗工作组推荐：加拿大心境与焦虑治疗网络（CANMAT）成人重性抑郁障碍使用消旋卡前列甲酯治疗工作组推荐。
Can J Psychiatry. 2021 Feb;66(2):113-125. doi: 10.1177/0706743720970860. Epub 2020 Nov 11.
3
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.加拿大情绪和焦虑治疗网络（CANMAT）工作组报告：治疗重度抑郁症的血清素致幻药物治疗。
Can J Psychiatry. 2023 Jan;68(1):5-21. doi: 10.1177/07067437221111371. Epub 2022 Aug 17.
4
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder.加拿大情绪与焦虑治疗网络（CANMAT）工作组关于在成人重度抑郁症患者中使用消旋氯胺酮的建议。
Can J Psychiatry. 2021 Dec;66(12):1102. doi: 10.1177/07067437211035276. Epub 2021 Aug 12.
5
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes.加拿大心境与焦虑治疗网络（CANMAT）2023 年成人重性抑郁障碍管理临床指南更新：加拿大心境与焦虑治疗网络（CANMAT）2023 年成人重性抑郁障碍管理临床指南更新
Can J Psychiatry. 2024 Sep;69(9):641-687. doi: 10.1177/07067437241245384. Epub 2024 May 6.
6
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.加拿大情绪与焦虑治疗网络（CANMAT）2016年成人重度抑郁症管理临床指南：第3节. 药物治疗。
Can J Psychiatry. 2016 Sep;61(9):540-60. doi: 10.1177/0706743716659417. Epub 2016 Aug 2.
7
Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder.加拿大心境与焦虑治疗网络（CANMAT）工作组报告：双相情感障碍和重性抑郁障碍中使用大麻的系统评价和建议。
Can J Psychiatry. 2023 May;68(5):299-311. doi: 10.1177/07067437221099769. Epub 2022 Jun 16.
8
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly.加拿大情绪与焦虑治疗网络（CANMAT）2016年成人重度抑郁症管理临床指南：第6节. 特殊人群：青少年、女性和老年人。
Can J Psychiatry. 2016 Sep;61(9):588-603. doi: 10.1177/0706743716659276. Epub 2016 Aug 2.
9
The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.静脉注射氯胺酮治疗伴有明显焦虑的成人难治性重度抑郁症和双相情感障碍的疗效：来自加拿大快速治疗卓越中心的结果。
J Psychopharmacol. 2021 Feb;35(2):128-136. doi: 10.1177/0269881120954048. Epub 2020 Oct 11.
10
The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders.加拿大情绪与焦虑治疗网络（CANMAT）工作组关于心境障碍合并焦虑障碍患者管理的建议。
Ann Clin Psychiatry. 2012 Feb;24(1):6-22.
引用本文的文献
1
Symptomatic and neurotrophic effects of GABAA receptor positive allosteric modulation in a mouse model of chronic stress.慢性应激小鼠模型中 GABAA 受体正变构调节的症状和神经营养作用。
Neuropsychopharmacology. 2022 Aug;47(9):1608-1619. doi: 10.1038/s41386-022-01360-y. Epub 2022 Jun 14.
本文引用的文献
1
The role of dissociation in ketamine's antidepressant effects.分离在氯胺酮抗抑郁作用中的作用。
Nat Commun. 2020 Dec 22;11(1):6431. doi: 10.1038/s41467-020-20190-4.
2
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.加拿大心境与焦虑治疗网络（CANMAT）成人重性抑郁障碍使用消旋卡前列甲酯治疗工作组推荐：加拿大心境与焦虑治疗网络（CANMAT）成人重性抑郁障碍使用消旋卡前列甲酯治疗工作组推荐。
Can J Psychiatry. 2021 Feb;66(2):113-125. doi: 10.1177/0706743720970860. Epub 2020 Nov 11.
3
Neurobiological biomarkers of response to ketamine.氯胺酮反应的神经生物学生物标志物。
Adv Pharmacol. 2020;89:195-235. doi: 10.1016/bs.apha.2020.05.003. Epub 2020 Jun 18.
4
A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.一项随机、交叉比较氯胺酮与电抽搐治疗重性抑郁发作的研究：加拿大抑郁症生物标志物整合网络研究方案。
BMC Psychiatry. 2020 Jun 2;20(1):268. doi: 10.1186/s12888-020-02672-3.
5
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.谷氨酸能神经传递：开发新型快速作用抗抑郁治疗方法的途径。
Int J Neuropsychopharmacol. 2019 Feb 1;22(2):119-135. doi: 10.1093/ijnp/pyy094.
6
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.一项关于N-甲基-D-天冬氨酸拮抗剂治疗难治性重度抑郁症的随机试验。
Arch Gen Psychiatry. 2006 Aug;63(8):856-64. doi: 10.1001/archpsyc.63.8.856.
Zotero 插件